Emerging drugs in the treatment of chronic cough

Brister, Danica; Wahab, Mustafaa; Rashad, Moaaz; Diab, Nermin; Kolb, Martin; Satia, Imran

doi:10.1080/14728214.2023.2203912

Cited by 3 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Respondents in our study listed the top-ranked benefit of a cough treatment as improving cough symptoms more quickly, preventing worsening of the cough, and increasing the number of days free from coughing. It is possible these goals may be achieved by new therapies on the horizon, including antagonists of P2X3 receptors, which are believed to be involved in cough reflex activation [ 34 ] and lack the sedative effects of centrally acting neuromodulators currently used off-label for the management of cough. One P2X3 receptor antagonist, gefapixant, has reported successful phase 3 outcomes [ 35 , 36 ] and received regulatory approval for RCC/UCC in Japan, Switzerland, and the European Commission.…”

Section: Discussionmentioning

confidence: 99%

Patient satisfaction with the management of refractory and unexplained chronic cough in Canada: Results from a national survey

Khan,

Brister,

Abraham

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Background Chronic cough (persisting for ≥8 weeks) is a common disorder affecting approximately 5 to 10% of adults worldwide that is sometimes refractory to treatment (refractory chronic cough [RCC]) or has no identifiable cause (unexplained chronic cough [UCC]). There is minimal information on the patient’s experience of RCC/UCC in Canada. The aim of this study was to evaluate the patient journey and perceptions related to RCC/UCC management in Canada. Methods Our exploratory study included Canadians in the Leger Opinion Panel and focused on individuals with RCC or UCC. Key entry criteria were: age ≥18 years, cough on most days for ≥8 weeks, no smoking within 1 year, no serious respiratory disease or lung cancer, and not taking angiotensin-converting enzyme inhibitors. Individuals who met entry criteria were invited to complete an approximately 30-minute online survey with questions on demographic characteristics, healthcare professional (HCP) interactions, diagnosis of underlying conditions, current treatments, and satisfaction with HCPs and chronic cough therapies. Results A total of 49,076 individuals completed the chronic cough screening questionnaire (July 30, 2021 to September 1, 2021): 1,620 (3.3%) met entry criteria for RCC or UCC, and 1,046 (2.1%) completed the online survey (mean age of 45 years, 61% female). Most respondents (58%) reported their chronic cough was managed by a general practitioner (GP). Forty-four percent of respondents did not have a diagnosis of an underlying condition for their cough. Breathing tests (39%) and chest imaging (34%) were the most common diagnostic tests. Cough suppressants (18%) were the most frequent current treatment. Respondents were moderately satisfied with their HCPs, but more than half considered their treatment ineffective and 34% had considered no longer seeking medical attention because of a lack of treatment success. Conclusions Individuals with RCC/UCC in Canada are largely unsatisfied with the effectiveness of treatment. Additional HCP education and new treatment options are needed to improve patient satisfaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient satisfaction with the management of refractory and unexplained chronic cough in Canada: Results from a national survey

Khan,

Brister,

Abraham

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

Burden of Disease Associated with Refractory and Unexplained Chronic Cough in Canada: Results from a National Survey

Brister,

Khan,

Abraham

et al. 2024

Lung

View full text Add to dashboard Cite

Unravelling vagal hypersensitivity in chronic cough: A distinct disease

Zhang,

Morice

2023

The Journal of Physiology

View full text Add to dashboard Cite

Chronic cough (CC) is a common but poorly understood disease that has a negative impact on quality of life. For years, clinicians have been trying to find the underlying diagnosis and using existing disease models to describe the patients’ illness. This presents a confusing picture of CC. Most patients with CC present with hypersensitivity of the cough reflex, which is characterised by laryngeal paraesthesia and an increased response to the tussive stimuli or an innocuous stimulus that would not trigger coughing in healthy people. Recently, it has been proposed that CC is a unique disease characterised by vagal hypersensitivity that projects to the central nervous system altering responsiveness. The evidence supports the hypothesis that CC is primarily a neurological disorder, consisting of different phenotypes. image

show abstract

Emerging drugs in the treatment of chronic cough

Cited by 3 publications

References 76 publications

Patient satisfaction with the management of refractory and unexplained chronic cough in Canada: Results from a national survey

Patient satisfaction with the management of refractory and unexplained chronic cough in Canada: Results from a national survey

Burden of Disease Associated with Refractory and Unexplained Chronic Cough in Canada: Results from a National Survey

Unravelling vagal hypersensitivity in chronic cough: A distinct disease

Contact Info

Product

Resources

About